Preliminary Clinical Study of 89sr in Palliation in Painful Skeletal Metastases

Guan Yihui,LIN Xiangtong,LIU Yongchang,JIN Shaojin,XUE Fangping,KUAI Dayu,Zhang Jingming

DOI: https://doi.org/10.3321/j.issn:0253-3219.2001.05.004

2001-01-01

Abstract:According to the requirements of department of special drug, bureau of drug administration, Chinese ministry of health, To testify the safety and efficiency of metastron injection solution imported from the Amersham Company, U.K. being underged. 27patients were treated with metastron for metastatic bony pain(MBP). 2 cases were excluded by interrupted follow-up, the other 25 cases with metastatic prostate carcinoma, lung cancer, breast cancer were evaluated in a standard quantitative pain measurement before the treatment.Pain scores of these patients were between 6—16. 1.48MBq/kg metastron was given intravenous. All the patients were observed at least 3 months. Pain score， immediate adverse reaction were observed . Results shown that clinical significant metastastic pain relief can be observed in most patients. Total efficiency was 72%， patients' life quality have been improved. There was mild decrease of white blood cell in 32% and platelet counts in 60% patients, but can recovered in most patients temperary except 1. In this case， liver function abnormal was also appeared. Significant increased pain (flare) occurred in 55.5% patients after the injection, the flare up pain had been lasting 3—7days, only one lasting more than 20 days. It was concluded that 89Sr is most effective in palliative therapy for MBP in-patient with prostate or breast carcinoma. In 94.4 % patients , the pain relief can lasted more than 3 months, but only one patient for 2 months.7 cases had repeated the bone scan after therapy，but no significant changes can be observed. There by 89 Sr was safe and effective for the treatment of MBP.